Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP)
Phase 1 Terminated
47 enrolled 43 charts
BIO-PSY
Phase NA Completed
193 enrolled 19 charts
CLVer
Phase 3 Completed
113 enrolled 42 charts
A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With Breast Cancer Gene (BRCA) Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast Cancer
Phase 1 Completed
70 enrolled 13 charts
Study to Evaluate the Efficacy and Safety of Sirolimus in Subjects With Metastatic, Mismatch Repair Deficient Solid Tumors After Immunotherapy
Phase 2 Terminated
6 enrolled 12 charts
DENOCINA
Phase 3 Completed
46 enrolled 49 charts
Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)
Phase 1 Completed
168 enrolled 59 charts
METEOR
Phase 3 Completed
658 enrolled 15 charts
MIM
Phase 3 Terminated
68 enrolled 13 charts
COMPLEMENT 1
Phase 3 Terminated
447 enrolled 32 charts
Nutritional Supplements and Hormonal Manipulations for Breast Cancer Prevention
Phase NA Completed
266 enrolled 20 charts
Pharmacogenetics of Metformin Action in PCOS
Phase NA Completed
55 enrolled 7 charts
A Phase IIa Study of the MEK Inhibitor Trametinib Monotherapy in the Treatment of Biliary Tract Cancers
Phase 2 Completed
20 enrolled 27 charts
Study to Determine the Safety, Maximum Tolerated Dose, Pharmacokinetics of Sorafenib (BAY43-9006)
Phase 1 Completed
158 enrolled 17 charts
A Phase I/II, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients With Chronic Lymphocytic Leukemia
Phase 2 Completed
10 enrolled 52 charts
A Phase II, Open Label, Single Arm, Multicenter Study of Chlorambucil in Japanese Previously Untreated Patients With Chronic Lymphocytic Leukemia
Phase 2 Completed
5 enrolled 23 charts